New Zealand health regulator approves use of Janssen COVID-19 vaccine
WELLINGTON, July 7 (Reuters) - New Zealand said on Wednesday that its health regulator Medsafe has given provisional approval for a coronavirus vaccine developed by Janssen, the pharmaceutical unit of Johnson & Johnson (JNJ.N).
The Janssen COVID-19 vaccine was approved for individuals 18 years of age and older, COVID-19 Minister Chris Hipkins said in an announcement.
"The medical evidence shows Janssen is a very safe and effective vaccine. It is a great addition to our vaccine options," Hipkins said, adding that the country had secured 2 million doses of the Janssen vaccine through an advance purchase agreement last year.
Our Standards: The Thomson Reuters Trust Principles.